Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study.

AUTOR(ES)

Ochs, G

RESUMO

Twenty eight patients with severe, intractable spasticity have been treated by chronic intrathecal administration of baclofen. An implantable programmable drug-administration-device (DAD) was used with a permanent intrathecal catheter. Infusion of 50 to 800 micrograms/day of baclofen completely abolished spasticity. Follow-up was up to two years. Therapeutic effect was documented by clinical assessment of tone, spasms and reflexes and by electrophysiological recordings of mono- and polysynaptic reflex activity. Complications and untoward side-effects of the procedure were few. This procedure is recommended for spasticity of spinal origin refractory to physiotherapy and oral medication. It is a preferable alternative to ablative surgical intervention.

Documentos Relacionados

• Empire Rheumatism Council. Cortisone/Aspirin Trial: Multi-Centre Controlled Trial Comparing Cortisone Acetate and Acetyl Salicylic Acid in the Long-Term Treatment of Rheumatoid Arthritis
• Empire Rheumatism Council *: Multi-Centre Controlled Trial of Cortisone Acetate and Acetyl Salicylic Acid in the Long-Term Treatment of Rheumatoid Arthritis † Results of Three Years' Treatment
• Intrathecal baclofen for treatment of spasticity.
• Ocular involvement in children with localised scleroderma: a multi‐centre study
• Frozen shoulder: a long-term prospective study.